申博sunbet

P R O D U C T S

BOSHUTAI®(Acarbose Tablets)

An oral medication for the treatment of diabetes

Boshutai® inhibits a class of enzyme, known as glycosidehydrolases, required for digesting carbohydrates into glucoses. Acarbose effectively reduces blood glucose level for patients with diabetes type 2, reaching adequate HbA1c level.

Functional features
Product advantages
Market prospects

Bossotel® is indicated for reducing postprandial blood glucose in people with low glucose tolerance and type 2 diabetes.

Bossotel ® is a first-line drug recommended by the "Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2017 Edition)", and has been included in the National Essential Drugs List and the National Medical Insurance Directory.

Acarbose is an α-glucosidase inhibitor (AGI), AGI has the highest sales among oral hypoglycemic agents in China.

Due to the stable and reliable source of API, Boshutai® has a cost advantage.

Boshutai® was successfully selected in the 13 provinces alliance procurement in 2022, which brings new opportunities for future development.

China is the world's largest diabetes country, According to the Frost & Sullivan report, in 2020, the prevalence of diabetes among Chinese adults was as high as 11.9%, and the prevalence in 2016 was 10.8%. The number of people with diabetes is expected to exceed 140 million in 2022.

Due to the late entry of new drugs such as GLP-1 receptor agonists into the Chinese market, traditional chemical oral hypoglycemic drugs still occupy the largest market share in my country's diabetes treatment drugs.